Drug Trial Radar · NCT06994845
Study to Assess the Efficacy, Pharmacokinetics, Safety and Tolerability of Iptacopan in Pediatric Patients With Primary IgAN
Last checked: Nov 20, 2026Latest source record: Sep 9, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
31
Planned (sponsor's estimate)
Start
Nov 27, 2025
Primary completion
Jun 28, 2030
Study completion Jun 30, 2030
Sponsor
- Lead sponsor
- Novartis PharmaceuticalsNovartis (NVS)
- Sponsor type
- Industry
- First posted
- May 29, 2025
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 2 years, up to 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The study is an open-label, single arm, multicenter, Phase III study to determine proteinuria reduction, pharmacokinetics (PK), safety and tolerability (including CV surveillance) of iptacopan in primary immunoglobulin A nephropathy (IgAN) pediatric patients aged 2 to \<18 years.
Conditions
- Primary Immunoglobulin A Nephropathy (IgAN)
Interventions
iptacopanDrug
Cohort 1 (12 to \< 18 years of age): Iptacopan 200 mg b.i.d.(twice daily) Cohort 2 (2 to \< 12 years old): Dosing tbd
Primary outcomes
What the sponsor says the trial is designed to measure.
- Log-transformed ratio to Baseline in UPCR (based on FMV)Time frame: Baseline, Week 38
Locations
20 sites in 8 countries. Site status is shown where the registry gives one.
Valley Childrens Hospital
Madera, California · Recruiting
Childrens Hospital Colorado
Aurora, Colorado · Recruiting
Univ of Florida Shands Division
Gainesville, Florida · Recruiting
Childrens Hospital of Philadelphia
Philadelphia, Pennsylvania · Recruiting
Prim Childrens Hosp Inv Pharm
Salt Lake City, Utah · Recruiting
Novartis Investigative Site
Córdoba, Córdoba Province, Argentina · Recruiting
Novartis Investigative Site
Brisbane, Queensland, Australia · Recruiting
Novartis Investigative Site
Nedlands, Western Australia, Australia · Recruiting
Novartis Investigative Site
Beijing, China · Recruiting
Novartis Investigative Site
Hangzhou, Zhejiang, China · Recruiting
Novartis Investigative Site
Hong Kong, Hong Kong · Recruiting
Novartis Investigative Site
Beersheba, Israel · Recruiting
Novartis Investigative Site
Haifa, Israel · Recruiting
Novartis Investigative Site
Jerusalem, Israel · Recruiting
Novartis Investigative Site
Petah Tikva, Israel · Recruiting
Novartis Investigative Site
Toyoake, Aichi-ken, Japan · Recruiting
Novartis Investigative Site
Kurume, Fukuoka, Japan · Recruiting
Novartis Investigative Site
Ōtsu, Shiga, Japan · Recruiting
Novartis Investigative Site
Fuchū, Tokyo, Japan · Recruiting
Novartis Investigative Site
Riyadh, Saudi Arabia · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.